✦ LIBER ✦

275 ORAL First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100)

Book ID: 118622855
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 262 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80573-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase III trial of paclitax

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

✍ R. Zon; Miller; M. Wang; J. Gralow; M. Dickler; M. Cobleigh; E. Perez; T. Shenki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Safety results from a phase III study (T

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Paclitaxel and bevacizumab as first-line

Paclitaxel and bevacizumab as first-line treatment in elderly women with HER-2 negative locally advanced or metastatic breast cancer: Preliminary results a multicenter phase II trial from Hellenic Oncology Research Group

✍ Vamvakas, L.; Karampeazis⁎, A.; Nikolaou, Ch.; Ardavanis, A.; Saloustros, E.; Ka 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 71 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB